Secondary Progression in Multiple Sclerosis: Neuronal Exhaustion or Distinct Pathology?
- PMID: 26987259
- DOI: 10.1016/j.tins.2016.02.001
Secondary Progression in Multiple Sclerosis: Neuronal Exhaustion or Distinct Pathology?
Abstract
Prevention of progression in neurological diseases, particularly in multiple sclerosis (MS) but also in neurodegenerative diseases, remains a significant challenge. MS patients switch from a relapsing-remitting to a progressive disease course, but it is not understood why and how this conversion occurs and why some patients never experience disease progression. Do aging and accumulation of neuronal damage induce progression, or do cognitive symptoms and accelerated grey matter (GM) atrophy point to distinct processes affecting networks? This review weighs accepted dogma against real data on the secondary progressive phase of the disease, highlighting current challenges in this important field and directions towards development of treatment strategies to slow or prevent progression of disability.
Keywords: conversion; multiple sclerosis; neurodegeneration; progression; secondary progressive; senescence.
Copyright © 2016 Elsevier Ltd. All rights reserved.
Similar articles
-
Sodium accumulation is associated with disability and a progressive course in multiple sclerosis.Brain. 2013 Jul;136(Pt 7):2305-17. doi: 10.1093/brain/awt149. Brain. 2013. PMID: 23801742
-
Gray matter atrophy in multiple sclerosis: a longitudinal study.Ann Neurol. 2008 Sep;64(3):255-65. doi: 10.1002/ana.21436. Ann Neurol. 2008. PMID: 18661561
-
Gray matter involvement in multiple sclerosis.Neurology. 2007 Feb 27;68(9):634-42. doi: 10.1212/01.wnl.0000250267.85698.7a. Neurology. 2007. PMID: 17325269 Review.
-
MRI evaluation of grey matter atrophy and disease course in multiple sclerosis: an overview of current knowledge.Acta Neurol Scand Suppl. 2014;(198):32-6. doi: 10.1111/ane.12234. Acta Neurol Scand Suppl. 2014. PMID: 24588504 Review.
-
Natural history of multiple sclerosis: a unifying concept.Brain. 2006 Mar;129(Pt 3):606-16. doi: 10.1093/brain/awl007. Epub 2006 Jan 16. Brain. 2006. PMID: 16415308
Cited by
-
Failed, Interrupted, or Inconclusive Trials on Neuroprotective and Neuroregenerative Treatment Strategies in Multiple Sclerosis: Update 2015-2020.Drugs. 2021 Jun;81(9):1031-1063. doi: 10.1007/s40265-021-01526-w. Epub 2021 Jun 4. Drugs. 2021. PMID: 34086251 Free PMC article. Review.
-
Multiple sclerosis and drug discovery: A work of translation.EBioMedicine. 2021 Jun;68:103392. doi: 10.1016/j.ebiom.2021.103392. Epub 2021 May 24. EBioMedicine. 2021. PMID: 34044219 Free PMC article. Review.
-
Back to the Future: The Role of Infections in Psychopathology. Focus on OCD.Clin Neuropsychiatry. 2022 Aug;19(4):248-263. doi: 10.36131/cnfioritieditore20220407. Clin Neuropsychiatry. 2022. PMID: 36101642 Free PMC article.
-
What Causes Deep Gray Matter Atrophy in Multiple Sclerosis?AJNR Am J Neuroradiol. 2019 Jan;40(1):107-108. doi: 10.3174/ajnr.A5942. Epub 2018 Dec 27. AJNR Am J Neuroradiol. 2019. PMID: 30591510 Free PMC article. No abstract available.
-
Applying causal models to explore the mechanism of action of simvastatin in progressive multiple sclerosis.Proc Natl Acad Sci U S A. 2019 May 28;116(22):11020-11027. doi: 10.1073/pnas.1818978116. Epub 2019 May 9. Proc Natl Acad Sci U S A. 2019. PMID: 31072935 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical